Comparison of the TCR ζ-chain with the FcR γ-chain in chimeric TCR constructs for T cell activation and apoptosis

Cancer Immunology, Immunotherapy

Volumn 51, Issue 8, 2002, Pages 417-423

  Ren Heidenreich, Lifen ^a   Mordini, Ryan ^b   Hayman, Thomas G ^c   Siebenlist, Ruth ^d   LeFever, Ann ^d  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b Pierce Milwaukee   (United States)

^c MARQUETTE UNIVERSITY   (United States)

^d ST LUKE S MEDICAL CENTER   (United States)

Author keywords

Adoptive cancer immunotherapy; Chimeric T cell receptor; FcR chain; T body; TCR chain

Indexed keywords

CYTOKINE; RECEPTOR; RECEPTOR SUBTYPE; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN; TYROSINE;

APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ACTIVATION; CELL DEATH; CHIMERA; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR CELL;

AMINO ACID MOTIFS; APOPTOSIS; CYTOKINES; DNA; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MODELS, GENETIC; NEOPLASMS; PHENOTYPE; POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, IGG; RECOMBINANT FUSION PROTEINS; RETROVIRIDAE; TUMOR CELLS, CULTURED;

EID: 0036047663     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-002-0301-7     Document Type: Article

References (38)

1. Fas ligand mediates activation-induced cell death in human T lymphocytes
2. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression
3. Specific cytotoxic T lymphocytes in gene therapy
4. The biology of the 17-1A antigen (EpCAM)
5. Adoptive tumor immunity mediated by lymphocytes bearing modified antigen-specific receptors
6. Recognition of human colon cancer by T cells transduced with a chimeric receptor gene
7. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors
8. Tumor-specific T-bodies: Toward clinical application
9. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product
10. Tumor-induced apoptosis of T lymphocytes: Elucidation of intracellular apoptotic events
11. The TCR ζ-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes
12. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen
13. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones
14. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes
15. Epithelial glycoprotein-2 expression is subject to regulatory processes in epithelial-mesenchymal transitions during metastases: An investigation of human cancers transplanted into severe combined immunodeficient mice
16. Characterization and expression of the gene for the human Fc receptor γ-subunit
17. Hypothesis: A recurrent, moderate activation fosters systemic autoimmunity - The apoptotic roles of TCR, IL-2 and Fas ligand
18. Antitumor activity of human T cells expressing the CC49ζ chimeric immune receptor
19. T cell signaling: A decision of life and death
20. Prolonged survival and tissue trafficking following adoptive transfer of CD4 zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects
21. Bypassing immunization: Optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA
22. Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors
23. Immunotherapy with T cells bearing chimeric antitumor receptors
24. + tumor cells by primary lymphocytes modified with chimeric T cell receptors
25. The fate of genetically modified T cells expressing chimeric receptors against EGP-2 tumor antigen following the tumor exposure
26. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
27. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma
28. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing ζ- or γ-signaling domains
29. Activation-induced apoptosis of mature T cells is dependent upon the level of surface TCR but not on the presence of CD3 ζ ITAM
30. Expression of Fas ligand in liver metastases of human colonic adenocarcinomas
31. TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis
32. T cell activation detemined by T cell receptor number and tunable thresholds
33. A T cell-dependent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen
34. Single chain Ig/γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity
35. Functional balance between T cell chimeric receptor density and tumor-associated antigen density: CTL-mediated cytolysis and lymphokine production
36. Signal transduction by lymphocyte antigen receptors
37. Signaling defects in T lymphocytes of patients with malignancy
38. Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: Selective rescue by caspase inhibition